| 2018-11 |
Biomimetic Syntheses of (±)‐Isopalhinine A, (±)‐Palhinine A, and (±)‐Palhinine D |
Angewandte Chemie. 2018 Nov;57(47):15572-15576. |
 |
| 2018-07 |
Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 4789. |
|
| 2018-07 |
Blockage of EGFR signaling repurposes tumor metabolism through suppression of glycolysis and Kreb cycle in head and neck cancer |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 3944. |
|
| 2018-05-10 |
Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition |
European Journal of Medicinal Chemistry. 2018 May 10;151:533-545. |
|
| 2018-04-25 |
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors |
European Journal of Medicinal Chemistry. 2018 Apr 25;150:491-505. |
|
| 2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer |
Cancer Science. 2018 Jan;109(Suppl. 1):739. |
|
| 2017-08-11 |
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer |
Scientific Reports. 2017 Aug 11;7:Article number 7972. |
|
| 2017-07 |
Drug repurposing for chronic myeloid leukemia: In silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors |
Journal of Biomolecular Structure and Dynamics. 2017 Jun;35(8):1833-1848. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2017-04 |
Toward the total syntheses of natural products containing trans-decalin skeleton from masked o-benzoquinone |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 516. |
|
| 2017-04 |
One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 185. |
|
| 2017-03-15 |
단백질 키나아제 억제제로서의 융합 다환 화합물 |
KR10-1718386/2017-03-15 |
|
| 2017-02-01 |
티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물 |
KR10-1703941/2017-02-01 |
|
| 2017-01-13 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
IN279196/2017-01-13 |
|
| 2016-12 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Oncotarget. 2016 Dec;7(52):86239-86256. |
|
| 2016-11-29 |
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design |
European Journal of Medicinal Chemistry. 2016 Nov 29;124:186-199. |
|
| 2016-11-23 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
EP2276346/2016-11-23 |
|
| 2016-10-28 |
做為蛋白激酶抑制劑的稠合多環化合物 |
HK1163089/2016-10-28 |
|
| 2016-10-13 |
오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물 |
KR10-1667822/2016-10-13 |
|
| 2016-07 |
Therapeutic polymeric nanoparticles and the methods of making and using thereof: A patent evaluation of WO2015036792 |
Expert Opinion on Therapeutic Patents. 2016 Jul;26(7):751-755. |
|
| 2016-06-23 |
作爲蛋白激酶抑制劑的稠合多環化合物 |
J/002109/2016-06-23 |
|
| 2016-06-07 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
CA2722220/2016-06-07 |
|
| 2016-03-23 |
作为蛋白激酶抑制剂的稠合多环化合物 |
CN102232071/2016-03-23 |
|
| 2016-03 |
Disruption of protein-protein interactions: Hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target survivin |
RSC Advances. 2016 Mar;6(38):31947-31959. |
|
| 2016-02-19 |
作為酪胺酸激酶抑制劑的稠合雙環及多環嘧啶化合物 |
HK1162509/2016-02-19 |
|
| 2016-02-04 |
作爲酪胺酸激酶抑制劑的稠合雙環及多環嘧啶化合物 |
J/001914/2016-02-04 |
|
| 2015-08-20 |
Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors |
AU2009241469/2015-08-20 |
|
| 2015-08 |
BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity |
Cancer Research. 2015 Aug;75:Abstract number 1754. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2015-08 |
Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180. |
|
| 2015-08 |
Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182. |
|
| 2015-07-31 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物 |
HK1151694/2015-07-31 |
|
| 2015-07-24 |
チロシンキナーゼ阻害剤としての融合2環および3環ピリミジン化合物 |
JP5781934/2015-07-24 |
|
| 2015-07-22 |
作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物 |
CN102264745/2015-07-22 |
|
| 2015-06-29 |
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification |
Scientific Reports. 2015 Jun 29;5:Article number 11702. |
|
| 2015-04-28 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物 |
J/001653/2015-04-28 |
|
| 2015-04-14 |
Fused multicyclic compounds as protein kinase inhibitors |
US9006252/2015-04-14 |
|
| 2015-02 |
Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors |
Journal of Medicinal Chemistry. 2015 Feb;58(3):1452-1465. |
|
| 2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity |
Journal of Computer-Aided Molecular Design. 2015 Jan;29(1):89-100. |
|
| 2014-12 |
BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71 |
Antiviral Research. 2014 Dec;112:18-25. |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-11 |
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):19-20. |
|
| 2014-10-29 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物 |
ZL200980115577.4/2014-10-29 |
|
| 2014-10-29 |
作为极光激酶抑制剂的稠合双环嘧啶化合物 |
CN102014627/2014-10-29 |
|
| 2014-10-21 |
化合物於製造治療病毒感染的藥物之用途 |
TWI457121/2014-10-21 |
|
| 2014-10 |
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer |
Expert Opinion on Investigational Drugs. 2014 Oct;23(10):1333-1348. |
|
| 2014-10 |
Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 2530. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-08 |
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors |
International Journal of Cancer. 2014 Aug;135(3):751-762. |
|
| 2014-08 |
Ligand efficiency based approach for efficient virtual screening of compound libraries |
European Journal of Medicinal Chemistry. 2014 Aug;83:226-235. |
|
ORCID:0000-0002-1332-005X6
